Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00069784
Other study ID # LTS6035
Secondary ID HOE901/4032
Status Completed
Phase Phase 3
First received October 1, 2003
Last updated January 24, 2013
Start date August 2003
Est. completion date December 2011

Study information

Verified date January 2013
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The primary objectives of the ORIGIN study were:

- To determine whether insulin glargine-mediated normoglycemia can reduce cardiovascular morbidity and/or mortality in people at high risk for vascular disease with either Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or early type 2 diabetes;

- To determine whether omega-3 fatty acids can reduce cardiovascular mortality in people with IFG, IGT or early type 2 diabetes.

The secondary objectives of the insulin glargine study were to determine if insulin glargine-mediated normoglycemia can reduce:

- total mortality (all causes);

- the risk of diabetic microvascular outcomes;

- the rate of progression of IGT or IFG to type 2 diabetes.


Description:

The ORIGIN study was conducted by the Population Health Research Institute in Hamilton, Ontario (Canada), working in conjunction with the sponsor, and an independent Steering Committee.

Routine visits were to occur at 2, 4, 8, and 16 weeks following randomization, then every four months for the rest of the study, for all participants

The duration of the study was based on the number of events observed (event-driven study) and was originally planned to be 5 years. In 2008-2009 ORIGIN's follow-up was extended by approximately 2 years, because of published literature of completed studies suggesting that a longer period of effective glycemic contrast between treatments might be needed to see an effect on cardiovascular events.


Recruitment information / eligibility

Status Completed
Enrollment 12537
Est. completion date December 2011
Est. primary completion date December 2011
Accepts healthy volunteers No
Gender Both
Age group 50 Years and older
Eligibility Inclusion criteria:

I1. Individuals with IFG and/or IGT, or early diabetes, as defined below.

Glucose tolerance status was determined by a 75 g oral glucose tolerance test (OGTT) that was performed fasting (ie, no consumption of food or beverage other than water for at least 8 hours) at the time of screening for all candidates who were not known to have diabetes. The qualifying OGTT could be obtained up to 4 weeks prior to screening provided that anti-diabetic therapy (if any) remained unchanged between the qualifying OGTT and the screening visit. Two plasma glucose values were drawn during the OGTT - a fasting value (FPG) and a value drawn two hours after the 75 g oral glucose load was administered (postprandial plasma glucose [PPG]).

- Impaired glucose tolerance (IGT), defined as a PPG value =140 and <200 mg/dL (ie, =7.8 and <11.1 mmol/L), with a FPG <126 mg/dL (7.0 mmol/L).

OR

- Impaired fasting glucose (IFG), defined as an FPG =110 and <126 mg/dL (=6.1 and <7 mmol/L), without diabetes mellitus (PPG must be <200 mg/dL [11.1 mmol/L]).

OR

- Early type 2 diabetes, defined as a FPG =126 mg/dL (7.0 mmol/L) or a PPG of =200 mg/dL (11.1 mmol/L), or a previous diagnosis of diabetes, and either:

- on no pharmacological treatment (while ambulatory) for at least 10 weeks prior to screening, with screening glycated hemoglobin <150% of the upper limit of normal (ULN) for the laboratory (eg, <9% if the ULN is 6%)

- or taking one oral antidiabetic drug (OAD) from among sulfonylureas (SU), biguanides, thiazolidinediones (TZDs), alpha-glucosidase inhibitors (AGIs), and meglitinides (MGTs) at a stable dose while ambulatory for at least 10 weeks at the time of screening (or for the 10 weeks prior to hospitalization if identified while hospitalized for a CV event), with screening glycated hemoglobin <133% of the ULN for the laboratory (eg, <8% if the ULN is 6%) if taking this medication at half-maximum dose or greater, and glycated hemoglobin <142% of the ULN for the laboratory (eg, <8.5% if the ULN is 6%) if taking this medication at less than half-maximum dose. Individuals taking combination products containing two or more OADs were not eligible.

I2. Men or women aged 50 years and older

I3. At least one of the following CV risk factors:

- previous myocardial infarction (MI) (= 5 days prior to randomization)

- previous stroke (= 5 days prior to randomization)

- previous coronary, carotid or peripheral arterial revascularization

- angina with documented ischemic changes (at least 2 mm ST segment depression on electrocardiogram during a Graded Exercise Test [GXT]; or with a cardiac imaging study positive for ischemia); or unstable angina with documented ischemic changes (either ST segment depression of at least 1 mm or an increase in troponin above the normal range but below the range diagnostic for acute myocardial infarction)

- microalbuminuria or clinical albuminuria (an albumin: creatinine ratio = 30 µg/mg in at least one or timed collection of urine with albumin excretion =20 µg/min or =30 mg/24 hours or total protein excretion =500 mg/24 hours)

- left ventricular hypertrophy by electrocardiogram or echocardiogram

- significant stenosis on angiography of coronary, carotid, or lower extremity arteries (ie, 50% or more stenosis)

- ankle-brachial index < 0.9.

I4. Provision of signed and dated informed consent prior to any study procedures.

I5. Ability and willingness to complete study diaries and questionnaires.

I6. Demonstrated ability to use the self-glucose-monitoring device, and to self-inject insulin prior to randomization.

I7. A negative pregnancy test for all women of childbearing potential (ie, ovulating, pre- menopausal, and not surgically sterile) and the agreement of these women to use a reliable method of birth control to prevent pregnancy during the duration of the study .

I8. Willingness to discontinue prior omega-3 PUFA supplements for the duration of the study.

Exclusion criteria

E1. Type 1 diabetes.

E2. Requiring ambulatory insulin treatment or uncontrolled or symptomatic hyperglycemia that is likely to require the addition of ambulatory insulin therapy or a new antidiabetic agent either before or within 2 weeks after randomization.

E3. Known anti-glutamic acid decarboxylase antibody (anti-GAD Ab) positivity in the past.

E4. Screening glycated hemoglobin =150% of the ULN for the laboratory (eg, =9% if the ULN is 6%).

E5. Unwillingness to inject insulin or perform self-monitoring of blood glucose.

E6. Nonadherence to the run-in requirement to inject placebo insulin and do capillary glucose monitoring for at least 4 days prior to randomization.

E7. Coronary artery bypass grafting (CABG) either planned at the time of screening, or CABG within the 4 years prior to screening - however, participants with angina, MI, or stroke since a previous CABG will be eligible for randomization, even if the last CABG was within 4 years.

E8. Serum creatinine >2.0 mg/dL (176 µmol/L) at screening.

E9. Active liver disease, or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >2.5 times ULN at screening.

E10. Chronic or recurrent treatment with systemic corticosteroids, or niacin treatment for hyperlipidemia.

E11. Heart failure of New York Heart Association (NYHA) Functional Class III or IV.

E12. Expected survival of <3 years for non-CV causes such as cancer.

E13. Any other factor likely to limit protocol compliance or reporting of adverse events (AEs).

E14. Unwilling or unable to discontinue TZDs.

E15. Simultaneous participation in any other clinical trial of an active pharmacologic agent.

E16. Unwillingness to permit sites to contact their primary physicians to communicate information about the study and the participant's data and treatment assignment.

E17. History of hypersensitivity to the investigational products.

E18. Previous randomization in this study.

E19. A prior heart transplant, or awaiting a heart transplant.

E20. Known infection with human immunodeficiency virus (HIV).

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
insulin glargine (HOE901)
Cartridges for use in a pen device, each containing 3 mL of insulin glargine 100 U/mL solution for injection
omega-3 polyunsaturated fatty acids (PUFA)
Gelatin capsules (containing icosapent ethyl esters 465 mg and doconexent ethyl esters 375 mg) for oral administration
placebo
Matching placebo gelatin capsules (containing olive oil) for oral administration
Device:
reusable pen device for insulin injection


Locations

Country Name City State
Argentina Sanofi-Aventis Administrative Office Buenos Aires
Australia Sanofi-Aventis Administrative Office Cove New South Wales
Austria Sanofi-Aventis Administrative Office Vienna
Belarus Sanofi-Aventis Administrative Office Minsk
Bermuda Sanofi-Aventis Administrative Office Hamilton
Brazil Sanofi-Aventis Administrative Office Sao Paulo
Canada Sanofi-Aventis Administrative Office Laval Quebec
Chile Sanofi-Aventis Administrative Office Santiago
China Sanofi-Aventis Administrative Office Beijing
Colombia Sanofi-Aventis Administrative Office Cali
Croatia Sanofi-Aventis Administrative Office Zagreb
Denmark Sanofi-Aventis Administrative Office Horsholm
Estonia Sanofi-Aventis Administrative Office Tatari
Finland Sanofi-Aventis Administrative Office Helsinki
France Sanofi-Aventis Administrative Office Paris
Germany Sanofi-Aventis Administrative Office Berlin
Hungary Sanofi-Aventis Administrative Office Budapest
India Sanofi-Aventis Administrative Office Mumbai
Ireland Makati City Dublin
Israel Sanofi-Aventis Administrative Office Netanya
Italy Sanofi-Aventis Administrative Office Milano
Korea, Republic of Sanofi-Aventis Administrative Office Seoul
Latvia Sanofi-Aventis Administrative Office Riga
Lithuania Sanofi-Aventis Administrative Office Vilnius
Mexico Sanofi-Aventis Administrative Office Mexico
Netherlands Sanofi-Aventis Administrative Office Gouda
Norway Sanofi-Aventis Administrative Office Lysaker
Philippines Sanofi-Aventis Administrative Office Makati City
Poland Sanofi-Aventis Administrative Office Warszawa
Romania Sanofi-Aventis Administrative Office Bucuresti
Russian Federation Sanofi-Aventis Aministrative Office Moscow
Slovakia Sanofi-Aventis Administrative Office Bratislava
South Africa Sanofi-Aventis Administrative Office Midrand
Spain Sanofi-Aventis Administrative Office Barcelona
Sweden Sanofi-Aventis Administrative Office Bromma
Switzerland Sanofi-Aventis Administrative Office Geneva
Turkey Sanofi-Aventis Administrative Office Istanbul
United Kingdom Sanofi-Aventis Administrative Office Guildford Surrey
United States Sanofi-Aventis Administrative Office Bridgewater New Jersey
Venezuela Makati City Caracas

Sponsors (2)

Lead Sponsor Collaborator
Sanofi Population Health Research Institute

Countries where clinical trial is conducted

United States,  Venezuela,  Argentina,  Australia,  Austria,  Belarus,  Bermuda,  Brazil,  Canada,  Chile,  China,  Colombia,  Croatia,  Denmark,  Estonia,  Finland,  France,  Germany,  Hungary,  India,  Ireland,  Israel,  Italy,  Korea, Republic of,  Latvia,  Lithuania,  Mexico,  Netherlands,  Norway,  Philippines,  Poland,  Romania,  Russian Federation,  Slovakia,  South Africa,  Spain,  Sweden,  Switzerland,  Turkey,  United Kingdom, 

References & Publications (6)

Badings EA, Dyal L, Schoterman L, Lok DJ, Stoel I, Gerding MN, Gerstein HC, Tijssen JG. Strategies to detect abnormal glucose metabolism in people at high risk of cardiovascular disease from the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial population. J Diabetes. 2011 Sep;3(3):232-7. doi: 10.1111/j.1753-0407.2011.00124.x. — View Citation

Hanefeld M, Koehler C, Hoffmann C, Wilhelm K, Kamke W, Gerstein H. Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes. Diabet Med. 2010 Feb;27(2):175-80. doi: 10.1111/j.1464-5491.2009.02915.x. — View Citation

ORIGIN Trial Investigators, Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012 J — View Citation

Origin Trial Investigators, Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J. 2008 Jan;155(1):26-32, 32.e1-6. Epub 2007 Nov 26. — View Citation

ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012 Jul 26 — View Citation

Ramachandran A, Riddle MC, Kabali C, Gerstein HC; ORIGIN Investigators. Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes: an analysis of baseline data from the ORIGIN trial. Diabetes Care. 2012 Apr;35(4):749-53. doi: 10.2337/dc11-1918. Epub 2012 Feb 8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Number of Patients With Various Types of Symptomatic Hypoglycemia Events Symptomatic hypoglycemia was defined as an event with clinical symptoms consistent with hypoglycemia, based on data recorded in the participant's diary. These were further categorized as confirmed (ie, with a concomitant home glucose reading =54 mg/dL [=3.0 mmol/L]) or unconfirmed.
Severe hypoglycemia was defined as an event with clinical symptoms consistent with hypoglycemia in which the participant required the assistance of another person, and one of the following:
the event was associated with a documented self-measured or laboratory plasma glucose level =36 mg/dL (=2.0 mmol/L), or
the event was associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration.
on-treatment period (median duration of follow-up: 6.2 years) Yes
Other Number of Patients With First Occurrence of Any Type of Cancer Data on cancers that occurred in association with hospitalizations were collected systematically in both groups from the start of the study. All reported cancers occurring during the trial (new or recurrent) were adjudicated by the Event Adjudication Committee. from randomization until study cut-off date (median duration of follow-up: 6.2 years) Yes
Primary Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI) or Nonfatal Stroke Number of participants with a first occurrence of one of the above events.
The outcome's evaluation is based on the number of such positively-adjudicated first events occurring for patients assigned to the study groups. Assessments of the above events were reviewed by the Event Adjudication Committee who was kept blinded to the group assignment of participants.
Statistical analysis is performed on the time from randomization to the first occurrence of the events. Number of participants with a composite endpoint (i.e. with first occurrence of CV death, nonfatal MI or nonfatal stroke) is provided in the first row of the statistical table.
from randomization until study cut-off date (median duration of follow-up: 6.2 years) No
Primary Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Revascularization Procedure or Hospitalization for Heart Failure (HF) Number of participants with a first occurrence of one of the above events (revascularization procedures included coronary artery bypass graft, percutaneous transluminal coronary angioplasty (PTCA) i.e. balloon, PTCA with stent, other percutaneous intervention, carotid angioplasty with/without stent, carotid endarterectomy, peripheral angioplasty with or without stent, peripheral vascular surgery, and limb amputation due to vascular disease).
The outcome's evaluation is based on the number of such positively-adjudicated first events occurring for patients assigned to the study groups. Assessments of the above events were reviewed by the Event Adjudication Committee who was kept blinded to the group assignment of participants.
Statistical analysis is performed on the time from randomization to the first occurrence of the events. Number of participants with a composite endpoint (i.e. with first occurrence of the events) is provided in the first row of the statistical table.
from randomization until study cut-off date (median duration of follow-up: 6.2 years) No
Secondary Total Mortality (All Causes) Number of deaths due to any cause from randomization until study cut-off date (median duration of follow-up: 6.2 years) No
Secondary Composite Diabetic Microvascular Outcome (Kidney or Eye Disease) The composite outcome used to analyze microvascular disease progression contained components of clinical events:
the occurrence of laser surgery or vitrectomy for diabetic retinopathy (DR);
the development of blindness due to DR;
the occurrence of renal death or renal replacement therapy; as well as the following laboratory-based events:
doubling of serum creatinine; or
progression of albuminuria (from none to microalbuminuria [at least 30 mg/g creatinine], to macroalbuminuria [at least 300 mg/g creatinine]).
from randomization until study cut-off date (median duration of follow-up: 6.2 years) No
Secondary Incidence of Development of Type 2 Diabetes Mellitus in Participants With IGT and/or IFG The incidence was determined by calculating the proportion of randomized participants without diabetes at randomization who either developed diabetes during the study or who were classified as having possible diabetes based on results of two oral glucose tolerance tests (OGTT) performed after the last follow-up visit (within 21-28 days for OGTT#1 and within 10-14 weeks for OGTT#2). from randomization until the last follow-up visit or last OGTT (median duration of follow-up: 6.2 years) No
See also
  Status Clinical Trial Phase
Completed NCT02801448 - Clinical Trial With Broccoli Sprout Extract to Patients With Type 2 Diabetes Phase 2
Withdrawn NCT01377961 - Effect of Lycopene and Isoflavones on Glucose Metabolism N/A
Completed NCT00754130 - MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011). Phase 1
Completed NCT00006305 - Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes Phase 3
Completed NCT00004983 - Education and Group Support for Diabetic Hispanics N/A
Completed NCT00010751 - Effects of Reiki on Painful Neuropathy and Cardiovascular Risk Factors Phase 2
Completed NCT02299388 - To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study Phase 4
Completed NCT00550329 - Bioequivalence Study Of Glucotrol XL 2.5 Mg Tablets Phase 1
Completed NCT00172536 - Effects of Exercise Training on Left Ventricular Function in Type 2 Diabetic Patients Post Coronary Artery Bypass Graft N/A
Completed NCT00071422 - Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes Phase 2
Completed NCT00029848 - Obese Patients With Type 2 Diabetes Phase 3
Completed NCT01608724 - The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus Phase 4
Completed NCT01694758 - OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA N/A
Completed NCT00979368 - Safety Study of BMS-816336 in Healthy Male Subjects Phase 1
Completed NCT00791661 - MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005) Phase 1
Active, not recruiting NCT02088658 - Technology Intensified Diabetes Education Study in African Americans N/A
Completed NCT01105429 - Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes Phase 1
Completed NCT00701090 - A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED) Phase 3
Completed NCT00952991 - The Effects of LAF237 on Gastric Function in Type 2 Diabetes Phase 3
Completed NCT00035984 - Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Phase 3